Christine Nai-Mei Sang, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Analgesics | 8 | 2016 | 1037 | 1.100 |
Why?
|
| Neuralgia | 6 | 2021 | 568 | 1.000 |
Why?
|
| Hyperalgesia | 4 | 2017 | 502 | 0.820 |
Why?
|
| Pain | 11 | 2020 | 4961 | 0.770 |
Why?
|
| Analgesics, Non-Narcotic | 3 | 2020 | 365 | 0.730 |
Why?
|
| Lidocaine | 2 | 2017 | 542 | 0.500 |
Why?
|
| Neuralgia, Postherpetic | 1 | 2013 | 38 | 0.450 |
Why?
|
| Narcotic Antagonists | 1 | 2017 | 562 | 0.430 |
Why?
|
| Pain Measurement | 11 | 2021 | 3418 | 0.420 |
Why?
|
| Cyclohexanecarboxylic Acids | 1 | 2013 | 143 | 0.420 |
Why?
|
| Receptors, Kainic Acid | 2 | 2004 | 88 | 0.410 |
Why?
|
| Isoquinolines | 3 | 2004 | 368 | 0.400 |
Why?
|
| Amines | 1 | 2013 | 278 | 0.400 |
Why?
|
| Neuropeptides | 1 | 2016 | 942 | 0.370 |
Why?
|
| Diabetic Neuropathies | 3 | 2021 | 410 | 0.360 |
Why?
|
| Receptors, AMPA | 2 | 2004 | 331 | 0.360 |
Why?
|
| Excitatory Amino Acid Antagonists | 2 | 2002 | 449 | 0.320 |
Why?
|
| Spinal Cord Injuries | 1 | 2016 | 930 | 0.310 |
Why?
|
| Glycoproteins | 1 | 2016 | 2260 | 0.310 |
Why?
|
| Pain Threshold | 3 | 2017 | 585 | 0.310 |
Why?
|
| Analgesics, Opioid | 4 | 2020 | 3667 | 0.310 |
Why?
|
| Tetrazoles | 3 | 2004 | 835 | 0.310 |
Why?
|
| Sensation | 1 | 2009 | 337 | 0.300 |
Why?
|
| Capsaicin | 3 | 1998 | 229 | 0.290 |
Why?
|
| gamma-Aminobutyric Acid | 1 | 2013 | 1123 | 0.290 |
Why?
|
| Peripheral Nervous System Diseases | 2 | 2009 | 700 | 0.280 |
Why?
|
| Spinal Cord | 3 | 2017 | 1807 | 0.270 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 2 | 2002 | 895 | 0.260 |
Why?
|
| Brain Concussion | 1 | 2017 | 1318 | 0.260 |
Why?
|
| Dextromethorphan | 2 | 2002 | 38 | 0.260 |
Why?
|
| Pain, Intractable | 1 | 2005 | 130 | 0.250 |
Why?
|
| Memantine | 1 | 2002 | 100 | 0.200 |
Why?
|
| Herpesviridae Infections | 1 | 2002 | 277 | 0.190 |
Why?
|
| Neurons, Afferent | 1 | 2003 | 508 | 0.180 |
Why?
|
| Hepatocyte Growth Factor | 1 | 2021 | 270 | 0.170 |
Why?
|
| Neuromuscular Depolarizing Agents | 1 | 2018 | 45 | 0.160 |
Why?
|
| Succinylcholine | 1 | 2018 | 66 | 0.160 |
Why?
|
| Fluoroscopy | 2 | 2002 | 924 | 0.160 |
Why?
|
| Multiple Sclerosis, Chronic Progressive | 1 | 2021 | 236 | 0.160 |
Why?
|
| Drug Synergism | 2 | 2017 | 1791 | 0.160 |
Why?
|
| Halothane | 1 | 2017 | 206 | 0.150 |
Why?
|
| Pain, Postoperative | 4 | 2017 | 1638 | 0.140 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2020 | 780 | 0.140 |
Why?
|
| Neurotensin | 1 | 2016 | 61 | 0.140 |
Why?
|
| Multiple Sclerosis, Relapsing-Remitting | 1 | 2021 | 520 | 0.130 |
Why?
|
| Plasmids | 1 | 2021 | 2305 | 0.130 |
Why?
|
| Injections, Spinal | 1 | 2016 | 303 | 0.130 |
Why?
|
| Cervical Vertebrae | 1 | 2002 | 973 | 0.130 |
Why?
|
| Dose-Response Relationship, Drug | 5 | 2016 | 10943 | 0.130 |
Why?
|
| Clinical Trials as Topic | 2 | 2009 | 7901 | 0.130 |
Why?
|
| Glycopyrrolate | 1 | 1994 | 33 | 0.130 |
Why?
|
| Priapism | 1 | 1994 | 31 | 0.130 |
Why?
|
| Penile Erection | 1 | 1994 | 97 | 0.120 |
Why?
|
| Maximum Tolerated Dose | 1 | 2016 | 891 | 0.120 |
Why?
|
| Steroids | 4 | 2003 | 931 | 0.110 |
Why?
|
| Nerve Fibers | 1 | 1996 | 688 | 0.110 |
Why?
|
| Analgesia | 1 | 2017 | 459 | 0.110 |
Why?
|
| Anesthetics, Inhalation | 1 | 2017 | 571 | 0.100 |
Why?
|
| Migraine Disorders | 1 | 2004 | 1620 | 0.100 |
Why?
|
| Skin | 2 | 2003 | 4353 | 0.100 |
Why?
|
| Double-Blind Method | 7 | 2021 | 12017 | 0.100 |
Why?
|
| Injections, Epidural | 2 | 2002 | 195 | 0.090 |
Why?
|
| Pemphigus | 1 | 1991 | 103 | 0.090 |
Why?
|
| Humans | 37 | 2021 | 742088 | 0.090 |
Why?
|
| Perioperative Care | 1 | 2017 | 997 | 0.090 |
Why?
|
| Fibromuscular Dysplasia | 1 | 1989 | 58 | 0.090 |
Why?
|
| Analgesia, Epidural | 2 | 2003 | 326 | 0.090 |
Why?
|
| Delayed-Action Preparations | 1 | 2013 | 965 | 0.090 |
Why?
|
| Nervous System Diseases | 1 | 2000 | 1617 | 0.080 |
Why?
|
| Contrast Media | 1 | 2002 | 5295 | 0.080 |
Why?
|
| TRPV Cation Channels | 1 | 2009 | 235 | 0.080 |
Why?
|
| Intraoperative Complications | 1 | 1994 | 1188 | 0.080 |
Why?
|
| Renal Artery | 1 | 1989 | 398 | 0.080 |
Why?
|
| Nociceptors | 2 | 2002 | 432 | 0.070 |
Why?
|
| Patient-Centered Care | 1 | 2017 | 1436 | 0.070 |
Why?
|
| Anesthesiology | 1 | 2017 | 1043 | 0.070 |
Why?
|
| Adiposis Dolorosa | 1 | 2006 | 12 | 0.070 |
Why?
|
| Erythema Nodosum | 1 | 2006 | 30 | 0.070 |
Why?
|
| Multiple Sclerosis | 1 | 2021 | 3076 | 0.070 |
Why?
|
| Anesthesia | 1 | 2017 | 1548 | 0.070 |
Why?
|
| Adrenergic Uptake Inhibitors | 1 | 2007 | 189 | 0.070 |
Why?
|
| Lipomatosis | 1 | 2006 | 112 | 0.070 |
Why?
|
| Treatment Outcome | 7 | 2021 | 62966 | 0.070 |
Why?
|
| Arterial Occlusive Diseases | 1 | 1989 | 793 | 0.060 |
Why?
|
| Drug Administration Schedule | 1 | 2013 | 4929 | 0.060 |
Why?
|
| Drug Evaluation | 1 | 2005 | 637 | 0.060 |
Why?
|
| Laminectomy | 2 | 2002 | 232 | 0.060 |
Why?
|
| Middle Aged | 14 | 2021 | 213127 | 0.060 |
Why?
|
| Thiophenes | 1 | 2007 | 590 | 0.050 |
Why?
|
| Neurofibromatosis 2 | 1 | 2005 | 380 | 0.050 |
Why?
|
| Peripheral Nervous System | 1 | 2002 | 150 | 0.050 |
Why?
|
| Drug Interactions | 1 | 2005 | 1458 | 0.050 |
Why?
|
| Adult | 15 | 2013 | 213712 | 0.050 |
Why?
|
| Ketorolac | 1 | 2000 | 77 | 0.050 |
Why?
|
| Diffusion | 1 | 2002 | 832 | 0.050 |
Why?
|
| Male | 16 | 2021 | 349538 | 0.040 |
Why?
|
| History, 20th Century | 2 | 2018 | 2739 | 0.040 |
Why?
|
| Neurilemmoma | 1 | 2005 | 547 | 0.040 |
Why?
|
| Injections, Intramuscular | 1 | 2021 | 548 | 0.040 |
Why?
|
| Models, Biological | 1 | 2016 | 9581 | 0.040 |
Why?
|
| Adenocarcinoma | 1 | 2017 | 6347 | 0.040 |
Why?
|
| False Positive Reactions | 1 | 2002 | 981 | 0.040 |
Why?
|
| Endpoint Determination | 1 | 2002 | 600 | 0.040 |
Why?
|
| Professional Competence | 1 | 2002 | 448 | 0.040 |
Why?
|
| Oral Surgical Procedures | 1 | 2000 | 168 | 0.040 |
Why?
|
| Malignant Hyperthermia | 1 | 2018 | 73 | 0.040 |
Why?
|
| Spasm | 1 | 2018 | 121 | 0.040 |
Why?
|
| Pain Clinics | 1 | 2017 | 49 | 0.040 |
Why?
|
| Chi-Square Distribution | 1 | 2004 | 3510 | 0.040 |
Why?
|
| Electric Stimulation | 1 | 2003 | 1770 | 0.040 |
Why?
|
| Neck | 1 | 2002 | 693 | 0.040 |
Why?
|
| Tooth Extraction | 1 | 1998 | 222 | 0.040 |
Why?
|
| Education | 1 | 2020 | 543 | 0.040 |
Why?
|
| Physical Stimulation | 1 | 1998 | 525 | 0.040 |
Why?
|
| Placebos | 1 | 2021 | 1677 | 0.030 |
Why?
|
| Hyperkalemia | 1 | 2018 | 218 | 0.030 |
Why?
|
| Digitoxin | 1 | 1975 | 22 | 0.030 |
Why?
|
| Acute Disease | 2 | 2004 | 7141 | 0.030 |
Why?
|
| Data Interpretation, Statistical | 1 | 2005 | 2714 | 0.030 |
Why?
|
| Microsomes, Liver | 1 | 1975 | 175 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2005 | 6483 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 2004 | 6365 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2013 | 15530 | 0.030 |
Why?
|
| Carbonic Anhydrases | 1 | 1975 | 115 | 0.030 |
Why?
|
| Aged | 6 | 2021 | 162944 | 0.030 |
Why?
|
| Female | 14 | 2021 | 379592 | 0.030 |
Why?
|
| Cadmium | 1 | 1975 | 212 | 0.030 |
Why?
|
| Iatrogenic Disease | 1 | 2017 | 545 | 0.030 |
Why?
|
| Product Surveillance, Postmarketing | 1 | 2018 | 430 | 0.030 |
Why?
|
| Ketamine | 1 | 2000 | 499 | 0.030 |
Why?
|
| Mercury | 1 | 1975 | 285 | 0.030 |
Why?
|
| Hot Temperature | 1 | 1998 | 1355 | 0.030 |
Why?
|
| Anesthesia, Epidural | 1 | 1994 | 227 | 0.030 |
Why?
|
| Injections, Intravenous | 1 | 1994 | 1420 | 0.030 |
Why?
|
| Drug Industry | 1 | 2018 | 744 | 0.030 |
Why?
|
| Animals | 8 | 2018 | 168561 | 0.030 |
Why?
|
| Drug Approval | 1 | 2018 | 740 | 0.030 |
Why?
|
| Anesthesia, Spinal | 1 | 1994 | 269 | 0.020 |
Why?
|
| Zinc | 1 | 1975 | 683 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2005 | 9144 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2009 | 18006 | 0.020 |
Why?
|
| United States Food and Drug Administration | 1 | 2018 | 1581 | 0.020 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2000 | 2276 | 0.020 |
Why?
|
| Piperidines | 1 | 1998 | 1602 | 0.020 |
Why?
|
| Quality of Life | 2 | 2021 | 12730 | 0.020 |
Why?
|
| Nerve Block | 1 | 1996 | 640 | 0.020 |
Why?
|
| Ulcer | 1 | 1991 | 209 | 0.020 |
Why?
|
| Pharyngitis | 1 | 1991 | 215 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2005 | 9941 | 0.020 |
Why?
|
| Mouth Diseases | 1 | 1991 | 239 | 0.020 |
Why?
|
| Angiography, Digital Subtraction | 1 | 1989 | 341 | 0.020 |
Why?
|
| Genital Diseases, Female | 1 | 1989 | 197 | 0.020 |
Why?
|
| United States | 4 | 2020 | 69693 | 0.020 |
Why?
|
| Sex Factors | 1 | 2002 | 10392 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2013 | 57683 | 0.020 |
Why?
|
| Contraceptives, Oral | 1 | 1989 | 563 | 0.020 |
Why?
|
| Pseudolymphoma | 1 | 2006 | 30 | 0.020 |
Why?
|
| Panniculitis | 1 | 2006 | 44 | 0.020 |
Why?
|
| Streptomyces griseus | 1 | 1975 | 6 | 0.020 |
Why?
|
| Hemerythrin | 1 | 1975 | 5 | 0.020 |
Why?
|
| Hexosaminidases | 1 | 1975 | 54 | 0.020 |
Why?
|
| Acetylglucosaminidase | 1 | 1975 | 70 | 0.020 |
Why?
|
| Subcutaneous Tissue | 1 | 2006 | 135 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2002 | 15056 | 0.020 |
Why?
|
| Age Factors | 2 | 2002 | 18355 | 0.020 |
Why?
|
| Tomography, Emission-Computed | 2 | 1999 | 1144 | 0.020 |
Why?
|
| Metalloproteins | 1 | 1975 | 100 | 0.020 |
Why?
|
| Opioid-Related Disorders | 1 | 2020 | 2062 | 0.020 |
Why?
|
| Time Factors | 3 | 2003 | 40054 | 0.020 |
Why?
|
| Lipoma | 1 | 2006 | 334 | 0.010 |
Why?
|
| HLA Antigens | 1 | 1989 | 1382 | 0.010 |
Why?
|
| Brain Mapping | 1 | 1999 | 6669 | 0.010 |
Why?
|
| Research Design | 1 | 2000 | 5979 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2002 | 19862 | 0.010 |
Why?
|
| Hydrogen-Ion Concentration | 3 | 1998 | 2552 | 0.010 |
Why?
|
| beta-Endorphin | 1 | 2002 | 53 | 0.010 |
Why?
|
| Codeine | 1 | 2002 | 49 | 0.010 |
Why?
|
| Respiration | 1 | 1989 | 1645 | 0.010 |
Why?
|
| Glucosephosphate Dehydrogenase Deficiency | 1 | 1983 | 89 | 0.010 |
Why?
|
| Brain | 2 | 1999 | 26343 | 0.010 |
Why?
|
| Epidural Space | 1 | 2002 | 124 | 0.010 |
Why?
|
| Neuroma, Acoustic | 1 | 2005 | 450 | 0.010 |
Why?
|
| Lens, Crystalline | 1 | 1983 | 388 | 0.010 |
Why?
|
| Anesthesia, Local | 1 | 2002 | 268 | 0.010 |
Why?
|
| Diagnosis, Differential | 2 | 2006 | 12958 | 0.010 |
Why?
|
| Glutathione | 1 | 1983 | 586 | 0.010 |
Why?
|
| Streptococcus pneumoniae | 1 | 1975 | 712 | 0.010 |
Why?
|
| Muscle Proteins | 1 | 1975 | 1159 | 0.010 |
Why?
|
| Oxygen Radioisotopes | 1 | 1999 | 76 | 0.010 |
Why?
|
| Acetaminophen | 1 | 2002 | 544 | 0.010 |
Why?
|
| Posture | 1 | 2002 | 958 | 0.010 |
Why?
|
| Cataract | 1 | 1983 | 833 | 0.010 |
Why?
|
| Ultrasonography | 1 | 1989 | 5978 | 0.010 |
Why?
|
| Carbon Dioxide | 2 | 1998 | 1141 | 0.010 |
Why?
|
| Digitoxigenin | 1 | 1975 | 11 | 0.010 |
Why?
|
| Carotid Body | 1 | 1975 | 26 | 0.010 |
Why?
|
| Vibration | 1 | 1998 | 325 | 0.010 |
Why?
|
| Regional Blood Flow | 1 | 1999 | 1525 | 0.010 |
Why?
|
| Chromatography, Thin Layer | 1 | 1975 | 223 | 0.010 |
Why?
|
| Hydroxylation | 1 | 1975 | 141 | 0.010 |
Why?
|
| Infusions, Intravenous | 1 | 2000 | 2271 | 0.010 |
Why?
|
| Anesthesia, General | 1 | 2002 | 1164 | 0.010 |
Why?
|
| Models, Psychological | 1 | 1999 | 810 | 0.010 |
Why?
|
| Kinetics | 2 | 1998 | 6474 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2002 | 35342 | 0.010 |
Why?
|
| NADP | 1 | 1975 | 225 | 0.010 |
Why?
|
| Biopsy | 1 | 2006 | 6756 | 0.010 |
Why?
|
| Adipose Tissue | 1 | 2006 | 3278 | 0.010 |
Why?
|
| Blood Flow Velocity | 1 | 1998 | 1423 | 0.010 |
Why?
|
| Kidney | 1 | 1989 | 7167 | 0.010 |
Why?
|
| Low Back Pain | 1 | 2002 | 955 | 0.010 |
Why?
|
| Protein Conformation | 2 | 1975 | 4013 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2002 | 77098 | 0.010 |
Why?
|
| Data Collection | 1 | 2002 | 3339 | 0.010 |
Why?
|
| Perception | 1 | 1999 | 1188 | 0.010 |
Why?
|
| Smoking | 1 | 1989 | 8969 | 0.010 |
Why?
|
| Functional Laterality | 1 | 1999 | 2290 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 1989 | 21719 | 0.010 |
Why?
|
| Affect | 1 | 1999 | 1473 | 0.010 |
Why?
|
| Species Specificity | 2 | 1975 | 2479 | 0.010 |
Why?
|
| Models, Neurological | 1 | 1999 | 1771 | 0.010 |
Why?
|
| Cattle | 1 | 1975 | 3923 | 0.010 |
Why?
|
| Hypertension | 1 | 1989 | 8455 | 0.010 |
Why?
|
| Coronary Circulation | 1 | 1975 | 1572 | 0.010 |
Why?
|
| Cerebrovascular Circulation | 1 | 1999 | 2732 | 0.010 |
Why?
|
| Oxygen | 2 | 1998 | 4169 | 0.010 |
Why?
|
| Binding Sites | 1 | 1975 | 6115 | 0.000 |
Why?
|
| Cnidaria | 1 | 1975 | 14 | 0.000 |
Why?
|
| Fucose | 1 | 1975 | 125 | 0.000 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 1975 | 3760 | 0.000 |
Why?
|
| Rats | 2 | 1983 | 24265 | 0.000 |
Why?
|
| Cardiovascular Diseases | 1 | 1989 | 15108 | 0.000 |
Why?
|
| Oligosaccharides | 1 | 1975 | 414 | 0.000 |
Why?
|
| Lens Cortex, Crystalline | 1 | 1983 | 21 | 0.000 |
Why?
|
| Glutathione Disulfide | 1 | 1983 | 28 | 0.000 |
Why?
|
| Protein Binding | 1 | 1975 | 9387 | 0.000 |
Why?
|
| Computers | 1 | 1975 | 611 | 0.000 |
Why?
|
| Heart | 1 | 1975 | 4462 | 0.000 |
Why?
|
| Glucosephosphate Dehydrogenase | 1 | 1983 | 207 | 0.000 |
Why?
|
| Rats, Inbred Strains | 1 | 1983 | 2191 | 0.000 |
Why?
|
| Structure-Activity Relationship | 1 | 1975 | 3133 | 0.000 |
Why?
|
| Carotid Sinus | 1 | 1975 | 45 | 0.000 |
Why?
|
| Vagotomy | 1 | 1975 | 83 | 0.000 |
Why?
|
| Chemoreceptor Cells | 1 | 1975 | 86 | 0.000 |
Why?
|
| Models, Molecular | 1 | 1975 | 5454 | 0.000 |
Why?
|
| Ventricular Function | 1 | 1975 | 416 | 0.000 |
Why?
|
| Vascular Resistance | 1 | 1975 | 936 | 0.000 |
Why?
|
| Pressure | 1 | 1975 | 1203 | 0.000 |
Why?
|
| Perfusion | 1 | 1975 | 1359 | 0.000 |
Why?
|
| Dogs | 1 | 1975 | 3910 | 0.000 |
Why?
|
| Heart Rate | 1 | 1975 | 4091 | 0.000 |
Why?
|
| Blood Pressure | 1 | 1975 | 8541 | 0.000 |
Why?
|